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One of the major problems in the clinical management of cancer
patients is the identification of an appropriate treatment strategy
for each patient. Although a number of prognostic variables that
can help select a treatment strategy for a patient have been identi-
fied (e.g. tumour type, tumour size, nodal status, hypoxic fraction,
proliferative status, etc.), many of these require biopsies or other
invasive techniques to obtain the information (Gatenby et al, 1988;
Höckel et al, 1991; Dressler, 1993; Hedley et al, 1993; Begg,
1995; Kaufman, 1996; Hayes, 1996). However, the usefulness of
the information from these invasive techniques is often limited by
the errors or artifacts associated with the sampling, preparation
and analytical procedures.
For example, the correct choice of chemotherapeutic agents or
the fractionation schedule for radiation therapy treatments
frequently depends on the proliferative status of a tumour
(Schabel, 1969; Thames et al, 1983; Begg et al, 1992; Corro et al,
1995, Takeda et al, 1996). It is well known that slowly prolifer-
ating tumours respond better to cell cycle non-specific agents
and/or conventional radiation therapy schedules, while rapidly
proliferating tumours respond better to cell cycle specific agents
and/or hyperfractionated radiation therapy schedules. At the
present time, the S phase fraction or the potential doubling time
(Tpot) obtained flow cytometrically on biopsy specimen is used as
the primary measure of a tumour’s proliferative status (Begg et al,
1992; Dressler, 1993; Begg, 1995; Corro et al, 1995). Although
these parameters are objective measures of a tumour’s prolifera-
tive status, the biopsy specimen may not be representative of the
whole tumour, and technical problems may often render unevalu-
able as many as 30–40% of the biopsy samples (Dressler, 1993;
Hedley et al, 1993). Even when the biopsy specimens are evalu-
able, the results of the flow cytometric assays performed on the
same sample in two or more institutions can vary enough to cause
many of the patients to be treated differently (Haustermans et al,
1995; Tsang et al, 1995). Consequently, the development of a non-
invasive procedure for determining the proliferative status of an
entire tumour might overcome many of these problems, and permit
a patient’s therapy to be selected with a more uniform measure of
the proliferative status as one of the prognostic variables.
A number of recent studies have reported an overexpression of
sigma receptors in a variety of human and rodent tumours (Bem
et al, 1991; Vilner and Bowen, 1992; Vilner et al, 1995). Sigma
receptors represent a class of proteins that were originally classi-
fied as a subtype of the opiate receptors (Walker et al, 1990;
Hellwell et al, 1994). Subsequent studies revealed that sigma
binding sites represent a distinct class of receptors. There are two
types of sigma receptors, s1 and s2. The s1 receptors have a mole-
cular weight of » 25 kDa, whereas the s2 receptors have a molec-
ular weight of » 21.5 kDa. The radioligand [3H](+)-pentazocine
has a high (» 3n M) affinity for s1 receptors and a low (> 1000 nM)
affinity for s2 receptors. The radioligand [3H]1,3 di-o-tolyguani-
dine ([3H]DTG) has equal affinity for both s1 and s2 receptors.
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guinea pig liver, human placental choriocarcinoma, rat brain and
mouse kidney (Hanner et al, 1996; Kekuda et al, 1996; Seth et al,
1997, 1998), the s2 receptor gene has not been cloned, probably
because no high affinity selective ligand for the s2 receptor protein
has been identified (Moebius et al, 1997). Little is known about
the function of these sigma receptors (Walker et al, 1990; Vilner
and Bowen, 1992; Moebius et al, 1997).
For the past several years, our group has been studying the
expression of s2 receptors as a potential biomarker of tumour cell
proliferation because every animal and human tumour cell line
studied to date overexpresses s2 receptors when compared to the
normal cell from which the tumour cell was derived (Bem et al,
1991; Vilner and Bowen, 1992; Hellwell et al, 1994; Vilner et al,
1995). Using the well-characterized in vitro mouse mammary
adenocarcinoma model, lines 66 (diploid) and 67 (aneuploid), we
demonstrated that the s2 receptor density in P-cells is 8–10 times
greater than the s2 receptor density in Q-cells (Mach et al, 1997;
Al-Nabulsi et al, 1999). In addition, we demonstrated that: (1) the
kinetics for the loss of s2 receptors from 66 cells during the P to Q
transition was identical to the kinetics for the loss of PCNA from
66 Q cells, (2) the kinetics for the increase in s2 receptors followed
the population growth kinetics when 10-day 66 Q- or 67 Q-cells
were recruited into the P-cell compartment by subculturing, (3)
there was no loss of s2 receptors from 9L rat brain tumour cells
that do not enter a Q state during the plateau phase, and (4) the
reduction of s2 receptors from MCF-7 cells treated with cytostatic
concentration of tamoxifen was quantitatively identical to the
reduction in Ki-67-positive cells, AgNOR scores and the IrdU
labelling index (Dong et al, 1997; Mach et al, 1997; Al-Nabulsi
et al, 1999). These in vitro data suggested that s2 receptors may be
a potential biomarker of cell proliferation in tumours, both before
and after treatment.
In the study reported here, the ratio of the number of s2 recep-
tors per P-cell to the number of s2 receptors per Q-cell was deter-
mined for both 66 and 67 tumours grown subcutaneously (s.c.) in
female nude mice. It was not possible to directly measure the
number of s2 receptors per P-cell or per Q-cell in these solid
tumours for numerous technical reasons. However, the s2 receptor
P:Q ratio could be obtained by first flow cytometrically quanti-
tating the percentage of P- and Q-cells in one half of each tumour
after labelling the tumour with bromodeoxyuridine (BrdU) every
8 h over a 48 h period, and then measuring the s2 receptor density
per mg of tumour using our standard s2 binding assay on a
membrane preparation from the other half of each tumour. The
close agreement between the s2 receptor P:Q ratio determined in
vitro and in situ suggests that: (1) the expression of s2 receptors is
likely to be a reliable biomarker of the proliferative status of solid
tumours and (2) radiologands that have a high affinity and a high
selectivity for the s2 receptor have the potential to assess the
proliferative status of human solid tumours using non-invasive
imaging techniques such as positron emission tomography (PET)
and single-photon emission computerized tomography (SPECT).
MATERIALS AND METHODS
Cell maintenance and tumour implantation
The 66 (diploid) and 67 (aneuploid) mouse mammary adenocarci-
noma cells were grown in Weymouth’s medium supplemented with
3% fetal calf serum, 6% newborn calf serum, 6% horse serum, 1%
glutamine, 80.5 mg ml–1 of streptomycin and 80.5 units ml–1 of
penicillin as previously described (Wallen et al, 1984a, 1984b). All
cells were rejuvenated from frozen stock and tested for
Mycoplasma at 3- to 6-month intervals. For the tumour implanta-
tions, exponentially growing 66 or 67 cells were trypsinized, and
single cell suspensions prepared at a concentration of » 107 cells
ml–1 in sterile saline. Approximately 1.5 ´ 106 cells were injected
s.c. in the inguinal region of adult (20–25 g) female nude mice to
produce the tumours.
BrdU labelling procedure
Three to four weeks after implantation, the P-cells in each tumour
were identified by labelling them with BrdU (Calbiochem-
Novabiochem Corp., La Jolla, CA, USA). BrdU was dissolved in
0.1 N sodium hydroxide, neutralized with 0.1 N hydrochloric acid
(HCl) and diluted in sterile saline. Approximately 100 mg kg–1 of
BrdU was injected intraperitoneally (i.p.) every 8 h over a 48-h
period (i.e. for at least 2 cell cycle times). At the time of labelling,
the tumours ranged in size from slightly less than 0.2 g to slightly
more than 2.0 g.
Preparation of the tumours for analysis
Within 2 h of the last BrdU injection, the mice were lightly anaes-
thetized with Ketamine•HCl (The Butler Co., Columbus, OH,
USA) and then killed by cervical dislocation. The tumour was
excised sterilely, cut in half, and each half weighed. To determine
the percentage of BrdU-labelled cells, the tumour was minced with
fine scissors and placed in a dissociation flask with 25–30 ml of an
enzyme cocktail consisting of 0.04% collagenase, 0.04% pronase
(» 2500 PUK/100 ml) and 0.05% DNAase I in Waymouth’s
medium without serum. After incubating for 30–45 min at 37°C
with continuous stirring, the material was filtered through an
80-mesh stainless steel filter to remove any large pieces of tissue.
The filtrate was centrifuged gently at 4°C, and the pellet resus-
pended in Waymouth’s medium. Finally, an aliquot of the cell
suspension was added to an equal volume of a trypan blue solu-
tion, and the cells counted on a haematocytometer.
Flow cytometry analysis
The single cell suspensions were gently centrifuged at 4°C, resus-
pended in phosphate-buffered saline (PBS) and fixed in 70%
ethanol at a final concentration of 1–2 ´ 106 ml–1. For the flow
cytometry analysis, 1.5 ´ 106 cells were first incubated for 20 min
at 37°C with 0.2 mg ml–1 of pepsin in 2 N HCl–PBS, washed twice
in PBS containing 0.5% fetal bovine serum (FBS), and then incu-
bated for 45 min with a mouse anti-BrdU antibody conjugated to
fluorescein isothiocyanate (Boehringer Mannheim, Indianapolis,
IN, USA). The cells were then washed in 1 ml of PBS containing
0.5% FBS and 0.5% Tween-20, incubated for 30 min in RNAase
(1 mg ml–1) and stained with propidium iodide (10 mg ml–1). All
flow cytometry was performed using a Coulter Epics flow
cytometer equipped with an air-cooled argon laser using an excita-
tion wavelength of 488 nm. In each experiment, cells isolated from
unlabelled 66 and 67 tumours were handled as described above in
order to set the gating parameters that compensate for autofluores-
cence and non-specific binding of the anti-BrdU monoclonal
antibody. These gating parameters were cross-checked in each
experiment using unlabelled and BrdU pulse-labelled 66 and 67
tissue culture cells. The gating parameters in each experimentExpression of sigma-2 receptors in solid tumours 1225
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were set to insure that less than 2% of the unlabelled cells had a
fluorescence signal equivalent to that of the weakest BrdU-
labelled cells in the tumour.
Cell survival assay
For the cell survival measurements, three dilutions of each single
cell suspension were prepared and seeded into five 60-mm Petri
dishes containing 5 ml of Waymouth’s medium. After 10–14 days
of incubation at 37°C in a humidified 5% carbon dioxide atmos-
phere, the medium was removed, and the colonies stained with
crystal violet prior to counting.
Morphological analysis
In one experiment, slices were cut from each half of the 66 or 67
tumours. The tumour slices were then fixed in 10% buffered
formalin and embedded in paraffin. After sectioning, the tissue was
stained with haematoxylin and eosin (H & E) and examined micro-
scopically. Cytospin slides were also made from each single cell
suspension, and the host cell composition of the 66 and 67 tumours
was determined microscopically after staining with Wright’s stain.
s2 receptor density assay
A detailed description of the assay for determining the s2 receptor
density in fmol mg–1 of protein has been published (Mach et al,
1997). Briefly, the tumour was homogenized using a Potter-
Elvejhem tissue grinder, and the membranes isolated and stored at
–80°C after determining the protein content by the method of
Bradford (1976). To determine the s2 receptor density, aliquots of
the membrane preparation (30–60 mg of protein) were incubated
with 4 nM [3H]DTG and varying amounts of unlabelled DTG
(0.1–1000 nM) in the presence of (+)-pentazocine (100 nM) to
mask the s1 sites. After 40 min at 25°C, the assay was terminated
by the addition of ice-cold 10 mM Tris–HCl (pH 8.0), and the
mixture rapidly filtered using a Brandel cell harvester
(Gaithersburg, MD, USA). The filters were then washed twice
with ice-cold buffer and prepared for liquid scintillation counting.
The saturation binding data were analysed with the Scatchard
program EBDA (Biosoft, Miltown, NJ, USA) using the COLD
option to calculate the KD and Bmax values. The dpm mg–1 of each
tumour was calculated using the radioactive counts obtained at
Bmax and the amount of protein recovered per mg of tumour in each
membrane preparation.
P:Q ratio of s2 receptors in solid tumours
The number of s2 receptors per P-cell and per Q-cell in solid
tumours cannot be determined directly by labelling the cells with
BrdU and sorting the P- and Q-cells on a cell sorter for subsequent
binding studies. The time required to sort an adequate number of
P- and Q-cells to perform the Scatchard analysis is prohibitive.
However, the P:Q ratio of the s2 receptors in solid tumors can be
obtained by an indirect method.
If we let:
x = the fraction of Q-cells mg–1 of tumour
1-x = the fraction of P-cells mg–1 of tumour
k = a constant with dimensions of dpm/receptor that converts
s2 receptors cell–1 to dpm cell–1 at saturation binding
then:
dpm mg–1 of tumour = kx (no. of s2 receptors per Q-cell) +
k(1–x) (no. of s2 receptors per P-cell) (1)
If both sides of the equation are divided by x, then:
dpm/mg of tumour = k (no. of s2 receptors per Q-cell) + k
x (no. of s2 receptors per P-cell)
([1–x]/x) (2)
Equation 2 has the form Y = a + bX; the equation for a straight
line. If one plots the dpm mg–1 of tumour divided by the fraction of
Q-cells mg–1 of tumour on the y-axis against the fraction of P-cells
mg–1 of tumour divided the fraction of Q-cells mg–1 of tumour on
the x-axis (e.g. [dpm mg–1 of tumour]/x vs [1–x]/x), a regression
analysis of the data should result in a straight line with the slope
equal to k (no. of s2 receptors per P-cell) and the intercept equal to
k (no. of s2 receptors per Q-cell). If the slope is divided by the
intercept, one obtains a ratio of the s2 receptors per P cell to the s2
receptors per Q cell for the solid tumours (Eq. 3) that can be
compared to the corresponding ratio generated in tissue culture.
If the fraction of P-cells mg–1 of tumour and the fraction of
Q-cells mg–1 of tumour are determined flow cytometrically on one
half of the tumour after repeated injections of BrdU over a time
period equal to at least 1.5–2 cell cycle times, and the dpm mg–1 of
tumour is determined from the binding of [3H]DTG to the s2 recep-
tors in membrane preparations from the other half of the tumour,
then all of the variables in equation 2 are known for each tumour,
and the s2 receptor P:Q ratio of each tumour can be calculated.
Data presentation
There were six independent experiments performed during this
6-month study. Each symbol in the Figures represents one indi-
vidual tumour from one of these independent experiments.
Therefore, the symbols in each figure denote results from a 66 or
67 tumour in a particular independent experiment.
RESULTS
In principle, the experimental design of this study is simple.
However, a number of technical problems have the potential to
seriously compromise the interpretation of the data collected in
these experiments. For example, if all of the tumours in these
experiments were of a similar size, the percentage of P- and
Q-cells and the s2 receptor density in each tumour might not vary
enough to generate a straight line whose slope and intercept could
be determined with the accuracy necessary to have confidence in
the calculated s2 receptor P:Q ratio. In addition, the s2 receptor
binding studies require three replicates at each time point, so one
half of the tumour must weigh ³ 200 mg. Consequently, the
tumours in the definitive experiment must have a minimum weight
of » 0.4 g and vary considerably in size (i.e. by a factor of » 3).
However, this variability in tumour size means that all technical
procedures must be free of size-related artifacts if a credible s2
receptor P:Q ratio for these 66 and 67 tumours is going to be
obtained.
slope = k(no. of s2 receptors per P-cell) = P:Q ratio of s2 receptors
intercept k(no. of s2 receptors per Q-cell) in solid tumours (3)1226 KT Wheeler et al
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Determination of the fraction of P- and Q-cells in 66 and
67 tumours
The fraction of P-cells mg–1 of tumour for these 66 and 67 sub-
cutaneous tumours was estimated by injecting BrdU every 8 h for
48 h, then killing the mouse, excising the tumour, enzymatically
dissociating the tumour into a single cell suspension, and flow cyto-
metrically determining the percentage of the total cells that were
labelled with BrdU. After enzymatic digestion, the total cell yield
from 66 and 67 tumours was a linear function of tumour size (Figure
1). For both the 66 and 67 tumours, the slopes of the lines were
similar, and the intercepts had values that were not statistically
different (P > 0.05%) from zero (Figure 1). Consequently, no size
artifacts were apparent with our tumour cell dissociation procedure.
The absence of size-related artifacts was also supported by the
morphological data obtained from the cytospin slides. Large
tumour cells comprised > 70% of the cells recovered from 66
tumours and > 60% of the cells recovered from 67 tumours.
Although the distribution of lymphocytes, macrophages,
neutrophils and necrotic cells differed between 66 tumours and 67
tumours, there was no difference in the distribution of these host
cells as a function of the tumour size (data not shown). Similarly,
there was no correlation between the size of the tumour and the
relative amount of necrosis present. Finally, the colony-forming
efficiency for the cells isolated from 67 tumours (» 13%) and 66
tumours (» 9%) did not vary with the tumour size and was not
affected by incorporation of the BrdU label. Thus, it is reasonable
to conclude that a representative 66 or 67 tumour cell sample was
always obtained in these experiments.
Although exponentially growing 66 and 67 tissue culture cells
that were pulse-labelled with BrdU contained as much BrdU per
cell as exponentially growing human tissue culture cells, the back-
ground fluorescence due to autofluorescence and non-specific
binding of the monoclonal antibody to the 66 and 67 tumour cells
was much higher because the commercially available antibody
was produced in mice. Consequently, the signal to noise ratio was
much less than that normally obtained with human tumour cells.
Two gating methods were employed to estimate the percentage of
BrdU-labelled 66 and 67 cells in the sample (Figure 2). The flow
cytometry data were displayed either as a bivariate distribution of
the BrdU content as a function of the cell’s position in the cell
cycle (Figure 2, row 1), or as a histogram of the BrdU content
(Figure 2, row 2). Gating parameters were selected so that ≤ 2% of
the unlabelled control cells (left panels) had fluorescence intensi-
ties sufficient to be considered BrdU-labelled cells. Although both
methods gave identical results (Figure 2), the line method (row 2)
was used to generate the data shown in the subsequent figures. The
percentage of BrdU-labelled cells (P-cells) ranged from > 40% to
> 70% in individual 66 and 67 tumours. There was no correlation
between the percentage of P-cells and tumour size for the 66
tumours, but the number of P-cells tended to decrease with
increasing tumour size for the 67 tumours (data not shown). The
percentage of BrdU-labelled cells in each half of a tumour was
similar (Figure 3), so it is reasonable to assume that the fraction of
P-cells determined flow cytometrically in one half of a 66 or 67
tumour is representative of the fraction of P-cells in the other half
of the same tumour.
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Determination of the s2 receptor density in 66 and 67
tumours
The s2 receptor density in 66 and 67 tumours was estimated from
the binding of [3H]DTG to membranes isolated from 66 and 67
tumours using (+)-pentazocine to mask the s1 sites. For both 66
and 67 tumours, the total membrane protein recovered was a linear
function of tumour size (Figure 4). The slopes of the lines were
similar for both tumours, and the intercepts had values that were
not statistically different (P > 0.05) from zero. The average KD
value calculated from the 3H-DTG binding data for twelve 66
tumours (26.2 ± 10.8 nM) and ten 67 tumours (39.7 ± 16.6 nM) was
slightly lower, but not statistically different (P > 0.1) from the
average KD values previously reported for 66 and 67 P- or Q-cells
grown in tissue culture (Mach et al, 1997; Al-Nabulsi et al, 1999).
In addition, the KD values for 66 and 67 tumours did not vary with
tumour size (data not shown). There was no correlation between
the s2 receptor density and tumour size for the 66 tumours, but the
s2 receptor density decreased with increasing tumour size for the
67 tumours (Figure 5). This result is consistent with the data
obtained in the BrdU-labelling study where the percentage of P-
cells appeared to vary with tumour size for the 67 tumours, but not
for the 66 tumours. Although the Bmax values were quite variable,
ranging from »1000 to > 4000 fmol mg–1 of protein for 66 tumours
and from »750 to »1800 fmol mg–1 of protein for the 67 tumours,
in nine out of ten cases, the s2 receptor density measured in one
half of a tumour was not statistically different (P > 0.05) from the
s2 receptor density measured in the other half of the same tumour
(Figure 6). Thus, it is reasonable to assume that the s2 receptor
density measured in one half of a tumour is representative of the s2
receptor density in the other half of the same tumour.
Determination of the s2 receptor P:Q ratio in 66 and 67
tumours
When the dpm mg–1 of tumour determined from the binding
studies was divided by the fraction of Q-cells mg–1 of tumour
determined from the BrdU-labelling studies and plotted in Figure 7
against the fraction of P-cells mg–1 of tumour divided by the frac-
tion of Q-cells mg–1 of tumour determined from the BrdU-labelling
studies, a linear function resulted as predicted (see Materials and
Methods). Dividing the slope of the line by the intercept resulted in
a s2 receptor P:Q ratio of 10.6 for the 66 tumours and 4.5 for the 67
tumours. These values agree within a factor of 2 with the s2
receptor P:Q ratio of 9.5 and » 8 determined from pure P and pure
Q populations of 66 and 67 mouse mammary adenocarcinoma
cells grown in tissue culture (Mach et al, 1997; Al-Nabulsi et al,
1999).
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The open and hatched bars are data from each half of a tumour as described in the legend to Figure 3. Data from these tumours are represented in the other
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DISCUSSION
Estimation of the P-cell compartment
In general, tumour cells in animals must be labelled with a DNA
precursor for 1.5–2 cell cycle times to ensure that all of the cycling
cells (P-cells) have been labelled. For example, although 9L rat
brain tumour cells have an average cell cycle and population
doubling time of » 20 h, time-lapse photography studies have
shown that, in an exponentially growing population, individual 9L
cells have cell cycle times as short as 13 h and as long as 35 h
(Ehmann and Wheeler, 1979). Despite this variability in cell cycle
times, all of these 9L cells were capable of dividing enough times
(> 6) to form a colony. A similar heterogeneity in cell cycle times
has also been described for other tumour cell lines (Ehmann et al,
1974). In our lab, 66 cells have a population doubling time in
tissue culture of 16.0 ± 1.0 h; 67 cells have a population doubling
time in tissue culture of 15.8 ± 0.3 h (Mach et al, 1997; Al-Nabulsi
et al, 1999). In this study, the 66 tumours had a volume doubling
time of about 24 h, and the 67 tumours had a volume doubling
time of about 30 h. Nothing else is known about the in situ cell
kinetics of these 66 and 67 tumours at this time. In selecting the
48 h BrdU-labelling period, it was assumed that the average in situ
cell cycle time for these 66 and 67 tumours would be at least as
long as that measured in tissue culture, and probably not as long as
the tumour volume doubling time. If the in situ cell cycle time for
these tumour cells were as short as that measured in tissue culture,
the percentage of BrdU-labelled cells measured in this study
would slightly overestimate the fraction of P-cells mg–1 of tumour.
However, slightly overestimating the P-cell compartment is not
expected to have a large effect on the s2 receptor P:Q ratio deter-
mined from the data in Figure 7.
Estimation of the s2 receptor density
The presence of host cells (lymphocyte, macrophages, neutrophils,
etc.) in the tumour also has the potential to complicate the inter-
pretation of these data. Most tumours are comprised of 30–60%
host cells that are predominantly non-proliferative or quiescent
(Siemann et al, 1984). The s2 receptor density of these terminally
differentiated host cells is unknown, but it is likely to be closer to
that of Q tumour cells than P tumour cells. Finally, the fraction of
the protein in the membrane preparation that comes from these
host cells is also unknown. Fortunately, most of the cells on the
cytospin slides prepared from nine 66 and nine 67 tumours were
clearly identified as large tumour cells (62 ± 12% and 71 ± 11%
respectively). Another 20± 8% of the cells from the 67 tumours
were either small tumour cells or lymphocytes that could not be
distinguished from each other. The small tumour cell/lymphocyte
component of the 66 tumours was 12 ± 5%. If it is assumed that
half of these small cells are tumour cells, > 80% of the cells in 67
tumours and » 70% of the cells in 66 tumours are tumour cells.
Given that, of the host cells, only the macrophages have a size
similar to the large tumour cells, and macrophages comprise only
8± 5% of the cells from 67 tumours and 10 ± 3% of the cells from
66 tumours, it is reasonable to suggest that > 90% of the protein in
the membrane preparations from 67 tumours and > 80% of the
protein in the membrane preparations from 66 tumours came from
tumour cells, not host cells. Although the presence of host cells in
these tumours will tend to bias the s2 receptor binding results by
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overestimating the Q-cell component, the close agreement
between the s2 receptor P:Q ratios measured for these 66 and 67
subcutaneous tumours and the 66 and 67 cells in tissue culture
indicates that the bias was minimal. This result is expected if
> 80% of the membrane protein for the binding studies came from
66 or 67 tumour cells. It should also be noted that a slight over-
estimation of the P-cell component in the BrdU-labelling studies
might have compensated for a slight overestimation of the Q-cell
component in the binding studies, when the in situ s2 receptor P:Q
ratio was calculated from the data in Figure 7.
Tumour size as a determinant of the P:Q ratio
In general, the fraction of Q cells in a tumour is anticipated to
increase as the tumour size increases and the tumour volume
doubling time increases. Both the BrdU-labelling data and the s2
receptor binding data (Figure 5) indicate that this generalization is
true for 67 tumours, but not for 66 tumours. Although the reason
for this difference between the tumours is not known, having an in
situ tumour model, where Bmax and the fraction of P- and Q-cells is
relatively constant as a function of tumour size, can be quite valu-
able when performing preclinical biodistribution studies of candi-
date s2-selective radioligands. If 66 tumours are used, tumour size
contributes minimally to the variability of the biodistribution data;
thereby making these experiments more efficient, more convenient
and less costly.
Comparison of the s2 receptor P:Q ratio in vivo and in
vitro
Usually, a statistical analysis of the data would be sufficient to
conclude that the s2 receptor P:Q ratio in 66 and 67 solid tumours
was identical to the s2 receptor P:Q ratio obtained with pure P and
pure Q populations of the same cells in tissue culture. However,
the parameters used to construct the s2 receptor P:Q ratio have
very large errors associated with them because both the experi-
mental design and the techniques used in the experiments are
complicated (Figure 7) (Mach et al, 1997; Al-Nabulsi et al, 1999).
For example, the day to day variability in the 3H-DTG binding
data required that the 66 or 67 P- and Q-cells be harvested from
tissue culture and analysed as matched pairs in order to obtain a
reliable estimate of the s2 receptor P:Q ratio (Mach et al, 1997;
Al-Nabulsi et al, 1999). When the errors on the individual para-
meters were used to calculate the errors on the s2 receptor P:Q
ratio, the 95% confidence interval was as large as the P:Q ratio for
the tissue culture data, and more than 5 times the P:Q ratio for the
solid tumour data. Consequently, a statistical analysis of the data
would not allow rejection of the null hypothesis that the in vivo
and in vitro s2 receptor P:Q ratios are equal, unless the in vivo
value is several times larger or smaller than the in vitro value.
Being cognizant of this potential problem, the samples for the in
vivo experiments were collected and blinded by one group of
investigators, and the critical components of the data were then
measured by two other groups of investigators at two different
institutions. After uncoding, the data was recombined to create the
points shown in Figure 7. Given that: (1) the limited data set for
each of the tumours could have exhibited a negative correlation,
a positive correlation, or no correlation and (2) the slope:intercept
ratio of any positive correlation (i.e. the s2 receptor P:Q ratio)
could have varied from very large negative values to very large
positive values, it is remarkable that the in vivo and in vitro esti-
mates of the s2 receptor P:Q ratio agree within a factor of 2. Thus,
it is not the statistical analysis of the data, but rather the close
agreement between the in vivo and in vitro s2 receptor P:Q ratios
which constitutes the most convincing argument for the claim
that the in vivo and in vitro s2 receptor P:Q ratios are actually
equal.
Implications for determining the proliferative status of
solid tumours by imaging
In recent years, several potential noninvasive imaging approaches
to assessing the proliferative status of solid tumours have been
investigated. In general, these approaches have involved the use of
radioligands that target a variety of metabolic processes that are
likely to vary with the proliferative status of a tumour. Examples
include: (1) [18F]FDG which measures glucose utilization; (2)
[11C]methionine ([11C]MET) which measures the rate of protein
synthesis, and [11C]thymidine ([11C]TdR) which measures the rate
of DNA synthesis (Minn et al, 1988; Martiat et al, 1988; Minn and
Soini, 1989; Leskinen-Kallio et al, 1991; Haberkorn et al, 1991;
Okada et al, 1992; Miyazawa et al, 1993). However, the correla-
tion coefficients for these metabolic biomarkers of cell prolifera-
tion with other known biomarkers of cell proliferation have ranged
from 0.6 to 0.8; values that are not sufficiently high to allow a
patient’s treatment to be individualized based on the results of
these metabolic imaging procedures.
Over the past several years, s2 receptors have been found on all
of the animal and human tumour cell lines that have been studied
(Bem et al, 1991; Vilner and Bowen, 1992; Vilner et al, 1995). In
general, the number of s2 receptors per tumour cell is equal to or
exceeds the number of s1 receptors per tumour cell. Using several
tissue culture models, our lab has demonstrated that s2 receptors
appear to be a biomarker of tumour cell proliferation (Mach et al,
1997; Al-Nabulsi et al, 1999). However, if the proliferative status
of solid tumours is to be determined using radioligands that bind to
s2 receptors and imaging techniques such as PET: (1) the s2
receptor P:Q ratio in situ should at least exceed three (Amano et al,
1998), (2) radioligands with a high selectivity and high affinity for
s2 receptors must be available (Moebius et al, 1997) and (3) endo-
geneous ligands must not interfere significantly with the binding
of the radiopharmaceutical in tumours and normal tissues (Liu
et al, 1992). The data in Figure 7 not only demonstrate that the in
situ s2 receptor P:Q ratio exceeds three for both 66 and 67 mouse
mammary tumours, but that the in situ s2 receptor P:Q ratio is also
in reasonable agreement with the 8–10 obtained in studies using
the corresponding tissue culture models. Secondly, our group has
recently synthesized a ligand that, in preliminary binding studies,
has both a high selectivity (> 30-fold) and a high affinity (» 3n M)
for s2 receptors. Finally, we have preliminary data using a non-
selective s2 radioligand and a s1-selective blocking agent to
label 66 tumours in female nude mice, which indicate that
tumour:blood, tumour:muscle and tumour:lung ratios of at least
15:1 should be achievable with a s2-selective radioligand having
an affinity of » 5n M (unpublished data). Consequently, combining
the data in Figure 7 which indicate that the expression of s2 recep-
tors may be a reliable biomarker of proliferation in solid tumours,
with our preliminary data on the properties and biodistribution of
radioligands that bind selectively to s2 receptors, makes it likely
that the proliferative status of solid tumors can be non-invasively
assessed using PET and/or SPECT imaging techniques in the near
future.1232 KT Wheeler et al
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